Back to School: How biopharma can reboot drug development. Access exclusive analysis here

1012 GLPG BMS UC
BioCentury & Getty Images

Product Development

Gilead’s Jyseleca has a leg up over BMS’s Zeposia in biologic-experienced UC patients 

Oct 13, 2020 | 12:22 AM GMT

Pivotal data in ulcerative colitis show two oral therapies — Jyseleca filgotinib from

Read the full 402 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE